Literature DB >> 20070391

A predictive model of response to peginterferon ribavirin in chronic hepatitis C using classification and regression tree analysis.

Masayuki Kurosaki1, Kotaro Matsunaga, Itsuko Hirayama, Tomohiro Tanaka, Mitsuaki Sato, Yutaka Yasui, Nobuharu Tamaki, Takanori Hosokawa, Ken Ueda, Kaoru Tsuchiya, Hiroyuki Nakanishi, Hiroki Ikeda, Jun Itakura, Yuka Takahashi, Yasuhiro Asahina, Megumu Higaki, Nobuyuki Enomoto, Namiki Izumi.   

Abstract

AIM: Early disappearance of serum hepatitis C virus (HCV) RNA is the prerequisite for achieving sustained virological response (SVR) in peg-interferon (PEG-IFN) plus ribavirin (RBV) therapy for chronic hepatitis C. This study aimed to develop a decision tree model for the pre-treatment prediction of response.
METHODS: Genotype 1b chronic hepatitis C treated with PEG-IFN alpha-2b and RBV were studied. Predictive factors of rapid or complete early virological response (RVR/cEVR) were explored in 400 consecutive patients using a recursive partitioning analysis, referred to as classification and regression tree (CART) and validated.
RESULTS: CART analysis identified hepatic steatosis (<30%) as the first predictor of response followed by low-density-lipoprotein cholesterol (LDL-C) (>/=100 mg/dL), age (<50 and <60 years), blood sugar (<120 mg/dL), and gamma-glutamyltransferase (GGT) (<40 IU/L) and built decision tree model. The model consisted of seven groups with variable response rates from low (15%) to high (77%). The reproducibility of the model was confirmed by the independent validation group (r(2) = 0.987). When reconstructed into three groups, the rate of RVR/cEVR was 16% for low probability group, 46% for intermediate probability group and 75% for high probability group.
CONCLUSIONS: A decision tree model that includes hepatic steatosis, LDL-C, age, blood sugar, and GGT may be useful for the prediction of response before PEG-IFN plus RBV therapy, and has the potential to support clinical decisions in selecting patients for therapy and may provide a rationale for treating metabolic factors to improve the efficacy of antiviral therapy.

Entities:  

Year:  2010        PMID: 20070391     DOI: 10.1111/j.1872-034X.2009.00607.x

Source DB:  PubMed          Journal:  Hepatol Res        ISSN: 1386-6346            Impact factor:   4.288


  22 in total

1.  Prediction of severe acute pancreatitis using classification and regression tree analysis.

Authors:  Wandong Hong; Lemei Dong; Qingke Huang; Wenzhi Wu; Jiansheng Wu; Yumin Wang
Journal:  Dig Dis Sci       Date:  2011-08-11       Impact factor: 3.199

2.  Pretreatment prediction of anemia progression by pegylated interferon alpha-2b plus ribavirin combination therapy in chronic hepatitis C infection: decision-tree analysis.

Authors:  Naoki Hiramatsu; Masayuki Kurosaki; Naoya Sakamoto; Manabu Iwasaki; Minoru Sakamoto; Yoshiyuki Suzuki; Fuminaka Sugauchi; Akihiro Tamori; Sei Kakinnuma; Kentaro Matsuura; Namiki Izumi
Journal:  J Gastroenterol       Date:  2011-06-17       Impact factor: 7.527

3.  Stratifying the risk of lymph node metastasis in undifferentiated-type early gastric cancer.

Authors:  Yukiko Asakawa; Masahiko Ohtaka; Shinya Maekawa; Mitsuharu Fukasawa; Yasuhiro Nakayama; Tatsuya Yamaguchi; Taisuke Inoue; Tomoyoshi Uetake; Minoru Sakamoto; Tadashi Sato; Yoshihiko Kawaguchi; Hideki Fujii; Kunio Mochizuki; Masao Hada; Toshio Oyama; Tomotaka Yasumura; Kosaku Omata; Atsushi Nishiyama; Keiichi Naito; Hideo Hata; Yoshiaki Haba; Kazuyuki Miyata; Haruhisa Saitoh; Yoichi Yamadera; Kazuo Miura; Akira Kawaoi; Tohru Abe; Hajime Tsunoda; Yuji Honda; Masayuki Kurosaki; Nobuyuki Enomoto
Journal:  World J Gastroenterol       Date:  2015-03-07       Impact factor: 5.742

4.  Genotype 3 and higher low-density lipoprotein levels are predictors of good response to treatment of recurrent hepatitis C following living donor liver transplantation.

Authors:  Sanjiv Saigal; Narendra S Choudhary; Neeraj Saraf; Dheeraj Gautam; Lipika Lipi; Amit Rastogi; Sanjay Goja; P Balachandran Menon; Prashant Bhangui; Sumana K Ramachandra; Arvinder S Soin
Journal:  Indian J Gastroenterol       Date:  2015-09-23

5.  Beneficial IL28B genotype associated with lower frequency of hepatic steatosis in patients with chronic hepatitis C.

Authors:  Hans L Tillmann; Keyur Patel; Andrew J Muir; Cynthia D Guy; Josephine H Li; Xiang Qian Lao; Alexander Thompson; Paul J Clark; Stephen D Gardner; John G McHutchison; Jeanette J McCarthy
Journal:  J Hepatol       Date:  2011-04-14       Impact factor: 25.083

6.  Pretreatment prediction of response to peginterferon plus ribavirin therapy in genotype 1 chronic hepatitis C using data mining analysis.

Authors:  Masayuki Kurosaki; Naoya Sakamoto; Manabu Iwasaki; Minoru Sakamoto; Yoshiyuki Suzuki; Naoki Hiramatsu; Fuminaka Sugauchi; Hiroshi Yatsuhashi; Namiki Izumi
Journal:  J Gastroenterol       Date:  2010-09-10       Impact factor: 7.527

7.  IL28B polymorphism is associated with fatty change in the liver of chronic hepatitis C patients.

Authors:  Mayu Ohnishi; Masataka Tsuge; Tomohiko Kohno; Yizhou Zhang; Hiromi Abe; Hideyuki Hyogo; Yuki Kimura; Daiki Miki; Nobuhiko Hiraga; Michio Imamura; Shoichi Takahashi; Hidenori Ochi; C Nelson Hayes; Shinji Tanaka; Koji Arihiro; Kazuaki Chayama
Journal:  J Gastroenterol       Date:  2012-02-18       Impact factor: 7.527

8.  Association of γ-glutamyl transferase (GGT) activity with treatment and clinical outcomes in chronic hepatitis C (HCV).

Authors:  James E Everhart; Elizabeth C Wright
Journal:  Hepatology       Date:  2013-04-05       Impact factor: 17.425

9.  Machine learning algorithms outperform conventional regression models in predicting development of hepatocellular carcinoma.

Authors:  Amit G Singal; Ashin Mukherjee; B Joseph Elmunzer; Peter D R Higgins; Anna S Lok; Ji Zhu; Jorge A Marrero; Akbar K Waljee
Journal:  Am J Gastroenterol       Date:  2013-10-29       Impact factor: 10.864

Review 10.  Attenuation coefficient (ATT) measurement for liver fat quantification in chronic liver disease.

Authors:  Nobuharu Tamaki; Masayuki Kurosaki; Yutaka Yasui; Kaoru Tsuchiya; Namiki Izumi
Journal:  J Med Ultrason (2001)       Date:  2021-06-24       Impact factor: 1.314

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.